Related Experiment Video
Updated: Jan 20, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation
Jame Abraham1,2, Albert J Montero1,2, Rachel C Jankowitz1,3,4
1NSABP Foundation, Pittsburgh, PA.
Purpose:
Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer eventually develop resistance to dual-antibody therapy with trastuzumab plus pertuzumab. Mechanisms of resistance have not been well elucidated. We evaluated the safety, tolerability, and efficacy of ado-trastuzumab emtansine (T-DM1) plus neratinib in patients who progressed on trastuzumab plus pertuzumab.
Patients And Methods:
In this 3 + 3 dose-escalation study, patients with metastatic breast cancer who progressed on trastuzumab, pertuzumab, and a taxane were treated with T-DM1 at 3.6 mg/kg intravenously every 3 weeks and dose-escalating neratinib at 120, 160, 200, or 240 mg/d orally.
Results:
Twenty-seven patients were treated across four dose-levels of neratinib. Dose-limiting toxicity in cycle 1 was grade 3 diarrhea in six patients and grade 3 nausea in one; no patient experienced grade 4 diarrhea, and there were no grade 5 toxicities. Other grade 3 to 4 toxicities included nausea (11%), dehydration (11%), electrolyte abnormality (19%), thrombocytopenia (15%), elevated transaminase levels (7%), and fatigue (7%). Twelve (63%) of 19 evaluable patients had an objective response. Responses occurred at all neratinib doses. Plasma cell-free DNA at baseline showed ERBB2 (HER2) amplification in 10 of 27 patients. Deep and more durable responses occurred in patients with cell-free DNA ERBB2 amplification. Two complete responders had high expression of total HER2 and p95HER2 in baseline tissue.
Conclusion:
We report the recommended phase II dose of T-DM1 3.6 mg/kg and neratinib 160 mg/d for this combination. Possible resistance mechanisms to HER2 antibodies may be loss of the HER2 receptor and high expression of p95HER2. These data provide the basis for an ongoing phase II study to better define the activity of this regimen.
Insights
This study found that combining ado-trastuzumab emtansine (T-DM1) with neratinib is a safe and effective treatment for HER2-positive metastatic breast cancer resistant to dual-antibody therapy. The recommended Phase II dose is T-DM1 3.6 mg/kg and neratinib 160 mg/d.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- HER2-positive metastatic breast cancer often develops resistance to trastuzumab and pertuzumab therapies.
- Understanding resistance mechanisms is crucial for developing new treatment strategies.
Purpose of the Study:
- To evaluate the safety, tolerability, and efficacy of ado-trastuzumab emtansine (T-DM1) combined with neratinib in patients with HER2-positive metastatic breast cancer who progressed on prior dual-antibody therapy.
- To identify potential resistance mechanisms to HER2-targeted therapies.
Main Methods:
- A 3+3 dose-escalation study treated 27 patients with metastatic breast cancer who progressed on trastuzumab, pertuzumab, and taxanes.
- Patients received T-DM1 (3.6 mg/kg IV every 3 weeks) and escalating doses of neratinib (120-240 mg/d orally).
- Safety, tolerability, objective response rate, and correlation with HER2 amplification in cell-free DNA were assessed.
Main Results:
- The recommended Phase II dose was determined to be T-DM1 3.6 mg/kg and neratinib 160 mg/d.
- Objective responses were observed in 12 (63%) of 19 evaluable patients across all neratinib doses.
- Patients with baseline ERBB2 (HER2) amplification in cell-free DNA showed deeper and more durable responses.
Conclusions:
- The combination of T-DM1 and neratinib demonstrates promising activity and acceptable toxicity in patients with heavily pretreated HER2-positive metastatic breast cancer.
- Potential resistance mechanisms include loss of HER2 receptor or high expression of p95HER2.
- Further investigation in a Phase II study is warranted to confirm these findings.
Related Concept Videos
Physiological Foundation of Stress
Role of the Sympathetic Nervous System
Adrenaline triggers the...
Social Foundations of Self II: The Generalized Other
Survey Safety
Theoretical Foundations of Nursing Practice
Theories provide a perspective to assess patients' conditions and organize data and methods. They also assist in analyzing and interpreting information. They represent a...
Social Foundations of Self I: Play and Game
Social Foundations of Self III: Self-Evaluation

